Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International, multicenter, randomized, double-blind study of vorinostat (MK-0683) or placebo in combination with bortezomib in patients with multiple myeloma
2008-003752-30Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Vorinostat + bortezomib with Placebo + bortezomib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2008; status: terminated.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-003752-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003752-30.